CROX vs REGN · rev $4.10B vs P/E 14, rev $14.34B
Crocs Inc (CROX) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Crocs Inc (CROX) is a footwear & accessories company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported CROX revenue for 2024-12-31 was $4.10B. Net income was $950.1M. Revenue was up 3.5% from 2023-12-31 to 2024-12-31. CROX currently screens at market cap $5.93B.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
CROX currently screens at market cap $5.93B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the CROX and REGN stock pages for the full models.
Not investment advice.